Healthy Individuals
Conditions
Interventions
Inatake of the food containing paprika-xanthophyll 9mg (once a day, 12weeks)
Intake of the placebo foods (once a day, 12weeks)
Sponsors
Ezaki Glico Co., Ltd.
Graduate school of Agricultural Sciences, Tohoku University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: (1)Subjects whose LDL-cho is is relatively high. (2)Subjects whose FMD is 0% or more and less than 6.0%. (3)Subjects whose BMI is 25.0 or more and less than 30.0. (4)Subjects who can visit the clinic facility on the scheduled visit date. (5)Subjects who have a briefing of the content of the present study, fully understanding and agreeing to its objective and being able to personally sign a written informed consent
Exclusion criteria
Exclusion criteria: (1) Subjects who have received some kind of treatment or care at the time of study participation. (2)Subjects who are during pregnancy or lactation, and intend to be pregnant during the study period. (3)Subjects who have a smoking habit (4)Subjects having blood sample of 200 mL within 4 week at the start of this study. (5)Subjects having blood sample of 400 mL within 16 week at the start of this study. (6)Subjects having blood sample of 1000 mL or more than within 48 hours at the start of intake of test food. (7)Subject in other clinical trials or trials. (8)Subjects who fall under any of the following items. a. Subjects who have heart, liver, or kidney disease (including complications of other diseases) b.Subjects with a history of cardiovascular disease. c.Subjects who have diabetes. d. Subjects with or having a history of serious diseases such as cancer and asthma. (9)Subjects who have a history of major surgery in the gastrointestinal tract such as gastrectomy, gastrointestinal suture, and intestinal resection. (10)Subjects who have severe food allergies. (11)Subjects who regularly use supplements, vegetable juice, and tomato juice that have the same ingredients as the test food. (12)Subjects who cannot refrain from taking Citrus unshiu during the test period (including the pre-observation period). (13)Subjects determined to be inappropriate by the investigator.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Flow-mediated dilation | — |
Countries
Japan
Contacts
Public ContactMasakazu Tomaru
Synapse Planning co.Ltd. Clinical Trial Session
Outcome results
None listed